Short answer
KalVista Pharmaceuticals, Inc. (KALV) filed an 8-K current report with the SEC on June 11, 2026 reporting Item 1.02 (Termination of a Material Definitive Agreement), Item 1.01 (Entry into a Material Definitive Agreement), Item 2.01 (Completion of Acquisition or Disposition of Assets), Item 3.01 (Notice of Delisting), Item 5.02 (Departure/Election of Directors or Officers), Item 5.03 (Amendments to Articles of Incorporation or Bylaws), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Supplemental indenture triggered by merger, modifying conversion mechanics for 3.250% Convertible Senior Notes due 2031.
- This filing includes Item 3.01, an item that often signal trouble.
KalVista Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Supplemental indenture triggered by merger, modifying conversion mechanics for 3.250% Convertible Senior Notes due 2031
- Each $1,000 note converts into $1,606.28 cash at and after merger closing
- $27.00 cash merger consideration defined as one unit of Reference Property
- Existing noteholders receive cash settlement rights rather than equity exposure to the post-merger company
Item 1.02 · Termination of a Material Definitive Agreement
- Termination of KalVista’s 2015, 2017, and 2021 equity incentive plans upon Offer and Merger closing
- Employee stock purchase plan terminated immediately before the Merger’s Effective Time
- Legacy equity programs ended as part of the transaction, eliminating future awards under those plans
Item 2.01 · Completion of Acquisition or Disposition of Assets
- KalVista shares ceased Nasdaq Global Market trading before the June 11, 2026 market open
- Merger consummation triggered delisting and Nasdaq Form 25 filing
- Form 15 planned to terminate Exchange Act registration and suspend ongoing SEC reporting
- Shareholders face reduced public-market liquidity and limited future company disclosures
Item 3.01 · Notice of Delisting
- Offer and merger closed, transferring KalVista control to Parent through Purchaser
- Parent funded merger consideration with cash on hand and financing
- No further change-of-control arrangements known to KalVista at filing time
Item 5.02 · Departure/Election of Directors or Officers
- Merger-installed governance: eight directors resigned, with John Hess becoming sole director and a Company officer
- Departures unrelated to operational disagreements, indicating transaction-driven leadership transition
- Transaction bonuses total $10.5 million: Palleiko $5.07M, Audhya $2.93M, Piekos $2.5M
- Bonuses payable within 60 days of closing, contingent on executives’ continued compliance with employment and restrictive-covenant agreements
- CFO Piekos received a Section 4999 excise-tax gross-up, creating uncertain additional merger-related compensation exposure
Item 5.03 · Amendments to Articles of Incorporation or Bylaws
- Certificate of incorporation and bylaws amended and restated in full as of the Effective Time
- Revised governing documents filed as Exhibits 3.1 and 3.2
- Potential shareholder-rights and governance changes require review of the exhibits before assessing impact
Item 7.01 · Regulation FD Disclosure
- Standard Regulation FD disclaimer language, not substantive company disclosure
- No investor-actionable operating, financial, or strategic information in the provided excerpt
Item EX-99.1 · Exhibit EX-99.1
- Chiesi completed KalVista acquisition on June 11, 2026, making KalVista a wholly owned subsidiary
- Cash consideration fixed at $27.00 per share, with 77.8% of outstanding shares tendered
- KalVista shares cancelled and ceased trading on Nasdaq Global Market, eliminating public-market liquidity
- Chiesi assumed ownership of EKTERLY, approved across the US, EU, UK, Japan and other markets
- Growth depends on EKTERLY commercialization, pediatric studies, pending approvals and successful integration into Chiesi’s rare-disease unit
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other KalVista Pharmaceuticals, Inc. 8-K filings
Get the next KALV 8-K as it lands
Follow KALV for push alerts, or ask the research agent what this filing means.